Literature DB >> 7696597

Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease.

K Blennow1, C Hesse, P Fredman.   

Abstract

Apolipoprotein E (ApoE) has been implicated in the pathogenesis of Alzheimer's disease (AD). ApoE is synthesized within the brain and has been suggested to be involved in the re-utilization of membrane lipids during neuronal repair and remyelination after injury. Spherical ApoE-containing lipoprotein particles are found in the cerebrospinal fluid (CSF). To study further the pathogenetic role of ApoE in degenerative brain disorders, we analysed ApoE in CSF. A significant (p < 0.001) reduction of CSF ApoE (1.5 +/- 1.2 ng ml-1) was found in AD compared with controls (5.0 +/- 2.7 ng ml-1). A less pronounced reduction was also found in frontal lobe dementia (3.1 +/- 1.5 ng ml-1; p < 0.05). These findings support the hypothesis that ApoE is involved in the pathogenesis of degenerative brain disorders such as AD. An increased reutilization of ApoE-lipid complexes in the brain, as part of a generalized repair process, may explain the low CSF ApoE in AD. Alternatively, the reduction of CSF ApoE may be caused by absorption of ApoE to senile plaques and neurofibrillary tangles.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7696597     DOI: 10.1097/00001756-199412000-00032

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  22 in total

1.  Measurement of apolipoprotein E (apoE) in cerebrospinal fluid.

Authors:  C Hesse; H Larsson; P Fredman; L Minthon; N Andreasen; P Davidsson; K Blennow
Journal:  Neurochem Res       Date:  2000-04       Impact factor: 3.996

2.  APOE ε 4 allele and CSF APOE on cognition in HIV-infected subjects.

Authors:  Marilou A Andres; Ute Feger; Avindra Nath; Sody Munsaka; Caroline S Jiang; Linda Chang
Journal:  J Neuroimmune Pharmacol       Date:  2010-12-24       Impact factor: 4.147

3.  Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease?

Authors:  J-C Lambert; D Mann; F Richard; J Tian; J Shi; U Thaker; S Merrot; J Harris; B Frigard; T Iwatsubo; C Lendon; P Amouyel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

4.  Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease.

Authors:  C Russo; G Angelini; D Dapino; A Piccini; G Piombo; G Schettini; S Chen; J K Teller; D Zaccheo; P Gambetti; M Tabaton
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-04       Impact factor: 10.154

6.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

7.  Central nervous system lipoproteins in Alzheimer's disease.

Authors:  T J Montine; K S Montine; L L Swift
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

8.  Apolipoprotein E in the brain and its role in Alzheimer's disease.

Authors:  J Poirier
Journal:  J Psychiatry Neurosci       Date:  1996-03       Impact factor: 6.186

9.  Levels of apolipoprotein A-II in cerebrospinal fluid in patients with neuroborreliosis are associated with lipophagocytosis.

Authors:  L Táborský; P Adam; O Sobek; M Dostál; J Dvoráková; L Dubská
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

10.  Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides.

Authors:  Romain Simon; Marion Girod; Catherine Fonbonne; Arnaud Salvador; Yohann Clément; Pierre Lantéri; Philippe Amouyel; Jean Charles Lambert; Jérôme Lemoine
Journal:  Mol Cell Proteomics       Date:  2012-08-23       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.